新型EGFRvIII-CAR转基因小鼠用于同系小鼠胶质母细胞瘤的严谨临床前研究
研究开发了一种携带鼠源化EGFRvIII-CAR的转基因小鼠品系,用于在同系小鼠胶质母细胞瘤(GBM)模型中产生高质量CAR-T细胞。该CAR-T细胞在体外和体内均显示特异性杀伤活性,单次静脉输注联合淋巴清除可延长荷瘤小鼠生存,但复发肿瘤出现EGFRvIII丢失;联合抗EP4化合物可带来部分小鼠长期生存。
要点
- 成功构建鼠源化EGFRvIII-CAR转基因小鼠,可在同系GBM模型中稳定产生CAR-T细胞。
- EGFRvIII-CAR-T细胞联合淋巴清除可延长荷瘤小鼠生存,但复发肿瘤出现EGFRvIII抗原丢失。
- 联合抗EP4化合物ONO-AE3-208可改善部分小鼠长期生存并延缓再挑战肿瘤生长。
核心结论
- 新型同系CAR转基因小鼠模型可作为解决临床相关问题和开发未来免疫治疗策略的有用工具。
研究设计与样本
- 研究首先建立鼠源化EGFRvIII-CAR,用逆转录病毒载体在C57BL/6J小鼠的同系SB28 GBM模型中验证功能。
- 随后构建在Rosa26位点携带Lox-Stop-Lox盒下游抗EGFRvIII-CAR的C57BL/6J背景转基因小鼠,并与CD4-Cre转基因小鼠交配使CAR在T细胞表达。
- 在体外和体内评估CART细胞功能,并评估CART联合抗EP4化合物ONO-AE3-208抑制SB28 GBM内免疫抑制性髓系细胞的效果。
主要发现
- 逆转录病毒载体和转基因来源的CART细胞均对SB28-EGFRvIII细胞显示特异性细胞毒活性。
- 在淋巴清除方案预处理后,单次静脉输注EGFRvIII-CART细胞延长了荷瘤小鼠生存,但复发肿瘤显示 profound EGFRvIII loss。
- 加入ONO-AE3-208后,一部分CART治疗小鼠获得长期生存,且这些存活小鼠对皮下再挑战的EGFRvIII+和亲本EGFRvIII- SB28均显示肿瘤生长延迟。
临床怎么用
- 该转基因小鼠模型可用于在同系小鼠GBM模型中严谨评估EGFRvIII-CAR-T免疫治疗。
- 临床前研究中可考虑联合淋巴清除预处理和抗EP4化合物以增强CAR-T疗效并应对抗原丢失。
局限性
- 研究为小鼠临床前模型,结果外推到人类需谨慎。
- 复发肿瘤出现EGFRvIII丢失,提示单靶点CAR-T治疗可能面临抗原逃逸。
- 联合ONO-AE3-208仅使一部分小鼠获得长期生存,疗效有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rigorous preclinical studies of chimeric antigen receptor (CAR) immunotherapy will require large quantities of consistent and high-quality CAR-transduced T (CART) cells that can be used in syngeneic mouse glioblastoma (GBM) models. To this end, we developed a novel transgenic (Tg) mouse strain with a fully murinized CAR targeting epidermal growth factor receptor variant III (EGFRvIII). METHODS: We first established the murinized version of EGFRvIII-CAR and validated its function using a retroviral vector (RV) in C57BL/6J mice bearing syngeneic SB28 GBM expressing EGFRvIII. Next, we created C57BL/6J-background Tg mice carrying the anti-EGFRvIII-CAR downstream of a Lox-Stop-Lox cassette in the Rosa26 locus. We bred these mice with CD4-Cre Tg mice to allow CAR expression on T cells and evaluated the function of the CART cells both in vitro and in vivo. To inhibit immunosuppressive myeloid cells within SB28 GBM, we also evaluated a combination approach of CART and an anti-EP4 compound (ONO-AE3-208). RESULTS: Both RV- and Tg-CART cells demonstrated specific cytotoxic activities against SB28-EGFRvIII cells. A single intravenous infusion of EGFRvIII-CART cells prolonged the survival of glioma-bearing mice when preceded by a lymphodepletion regimen with recurrent tumors displaying profound EGFRvIII loss. The addition of ONO-AE3-208 resulted in long-term survival in a fraction of CART-treated mice and those survivors demonstrated delayed growth of subcutaneously re-challenged both EGFRvIII+ and parental EGFRvIII- SB28. CONCLUSION: Our new syngeneic CAR Tg mouse model can serve as a useful tool to address clinically relevant questions and develop future immunotherapeutic strategies.
引用
- Chuntova P, Hou Y, Naka R, et al. Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice. Neuro Oncol. 2022. PMID: 34347086. doi:10.1093/neuonc/noab182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。